Skip to main content
NewslettersWatchlist

Becton Dickinson and Company(BDX-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low230.47
Day High233.25
Open:232.61
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Barchart
Buy on the Dip: These 3 Stocks Just Hit 52-Week Lows
Barchart
3 Highest-Rated Dividend Kings To Buy and Hold Forever
Newswire.ca
Zeus Names New Chief Executive Officer
Barchart
3 Undervalued Dividend Aristocrats Trading Just Above Their 52 Week Lows
Motley Fool
3 Dividend Kings of Healthcare Stocks to Buy Hand Over Fist in March
Baystreet
Light Week for Macroeconomic Numbers
PR Newswire
BD Named Among the 100 Best Corporate Citizens of 2023
PR Newswire
BD Names Greg Rodetis as Senior Vice President of Investor Relations
PR Newswire
BD, Casella Complete Industry-First Pilot Recycling 40,000 Pounds of Used Medical Devices
PR Newswire
BD to Announce Fiscal 2023 Fourth Quarter and Full Year Financial Results
PR Newswire
BD Ranks in Top 10 for Transparency, Awarded Best Code of Conduct in 2023 U.S. Transparency Awards
PR Newswire
Navigate BioPharma Services, Inc. Announces Collaboration with BD (Becton, Dickinson and Company) to Advance Capabilities for Clinical Phases of Drug Development
The Globe and Mail
Six health care stock picks to play defence in times of market volatility
PR Newswire
BD to Present at Investor Healthcare Conferences
PR Newswire
BD Reports Third Quarter Fiscal 2023 Financial Results
PR Newswire
BD Receives 510(k) Clearance for COVID-19, Influenza A/B, RSV Molecular Combination Test
PR Newswire
BD Board Declares Dividend
Barchart
Stocks End Moderately Higher as Earnings Season Heats Up
PR Newswire
BD Names Joanne Waldstreicher to Board of Directors
Motley Fool
Why Shares of Becton, Dickinson Rose Monday
Barchart
Stocks Post Moderate Gains on Strength in Energy Stocks and Lower Bond Yields
PR Newswire
BD CEO Tom Polen Addresses FDA 510(k) Clearance of BD Alaris™ Infusion System
Barchart
Stocks Set to Open Higher as Investors Await Fed Meeting, Big Tech Earnings
PR Newswire
BD Receives FDA 510(k) Clearance for Updated BD Alaris™ Infusion System
PR Newswire
BD Issues FY 2022 ESG Report, Highlights Notable Progress in Energy and Waste Reduction, Health Care Access and Diversity
PR Newswire
BD Recognized as a Best Place to Work for Disability Inclusion
PR Newswire
BD to Announce Financial Results for its Third Quarter of Fiscal 2023
PR Newswire
BD to Sell Surgical Instrumentation Platform to STERIS
PR Newswire
BD Launches New Robotic System to Automate Clinical Flow Cytometry
PR Newswire
BCAL Findings Presented at 2023 ASCO Annual Meeting
MarketBeat
Intuitive Surgical Gives Buying Opportunity Off Its 52 Week Highs
PR Newswire
BD Advances Prefilled Flush Syringe with Integrated 'Scrub-the-Hub' Innovation

Profile

Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.